pH-D Feminine Health Boric Acid Suppositories: Unapproved Drug Recall
pH-D Feminine Health recalls boric acid vaginal suppositories sold without FDA approval. These products may not be safe for use without an approved drug application.
Recall notice
Marketed without an Approved NDA/ANDA.
Contact the company
What happened, in plain English
pH-D Feminine Health is recalling boric acid vaginal suppositories because they were marketed without FDA approval. This means the product may not be safe for use without an approved drug application. Read more at govinfonow.com/recall/36795-ph-d-feminine-health-boric-acid-suppositories-unapproved-drug-recall.
Source Summary by GovInfoNow · govinfonow.com/recall/36795-ph-d-feminine-health-boric-acid-suppositories-unapproved-drug-recall · Updated October 4, 2026 · FDA enforcement record: FDA #D-1627-2020
Cite this page
“pH-D Feminine Health Boric Acid Suppositories: Unapproved Drug Recall.” GovInfoNow, updated October 4, 2026. https://govinfonow.com/recall/36795-ph-d-feminine-health-boric-acid-suppositories-unapproved-drug-recall. Based on FDA recall #D-1627-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1627-2020%22&limit=1).
Why it’s dangerous
The product was sold without an FDA-approved drug application, meaning it may not meet safety and effectiveness standards. Without proper approval, the product could cause harm if used improperly.
Who’s affected
Women who purchased these suppositories from retailers like Amazon or pharmacy chains. Those with medical conditions requiring vaginal suppositories are at higher risk.
How to tell if you have this one
Check for the brand pH-D Feminine Health on the packaging. Look for lot numbers: 2PA20021, 2PA20061, D-160, D-155, D-162, or 7PA20071. The product was sold with UPC code 3 49597 00044 5.
- Brand
pH-D Feminine Health- Product
pH-D Feminine Health Boric Acid Vaginal Suppositories, 24 vaginal suppositories per box, 600 mg each, pH-D Feminine- Category
Drug
What to do — step by step
Check Product Details
Look for the lot numbers listed: 2PA20021, 2PA20061, D-160, D-155, D-162, or 7PA20071.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the U.S.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 18 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1627-2020 (September 2, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1627-2020 to see it in context.
- Plain-language summary written by qwen3:4b on October 4, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.